Adherence to post-exposure prophylaxis for non-forcible sexual exposure to HIV: A systematic review and meta-analysis

AIDS and Behavior

Volumn 18, Issue 2, 2014, Pages 217-225

  Oldenburg, Catherine E ^a   Bärnighausen, Till ^a   Harling, Guy ^a   Mimiaga, Matthew J ^a,b,c   Mayer, Kenneth H ^c,d  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c FENWAY INSTITUTE   (United States)

^d BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

HIV; Medication adherence; Meta analysis; Post exposure prophylaxis

Indexed keywords

HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEDICATION COMPLIANCE; META ANALYSIS; POST EXPOSURE PROPHYLAXIS; REVIEW;

HIV INFECTIONS; HUMANS; MEDICATION ADHERENCE; POST-EXPOSURE PROPHYLAXIS;

EID: 84893833664     PISSN: 10907165     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10461-013-0567-0     Document Type: Review

References (49)

1. Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27):2587-99.
2. Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367(5):399-410.
3. Thigpen MC, Kebaabetswe PM, Paxton LA, Smith DK, Rose CE, Segolodi TM, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012;367(5):423-34.
4. Van Damme L, Corneli A, Ahmed K, Agot K, Lombaard J, Kapiga S, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2012;367(5):411-22.
5. Minnis AM, Gandham S, Richardson BA, Guddera V, Chen BA, Salata R, et al. Adherence and acceptability in MTN 001: a randomized cross-over trial of daily oral and topical tenofovir for HIV prevention in women. AIDS Behav. 2012;17(2):737-47.
6. Elst EM, Mbogua J, Operario D, Mutua G, Kuo C, Mugo P, et al. High acceptability of HIV pre-exposure prophylaxis but challenges in adherence and use: qualitative insights from a Phase I trial of intermittent and daily prep in at-risk populations in Kenya. AIDS Behav. 2012;17(6):2162-72.
7. Mutua G, Sanders E, Mugo P, Anzala O, Haberer JE, Bangsberg D, et al. Safety and adherence to intermittent pre-exposure prophylaxis (PrEP) for HIV-1 in African men who have sex with men and female sex workers. PLoS One. 2012;7(4):e33103.
8. Ware NC, Wyatt MA, Haberer JE, Baeten JM, Kintu A, Psaros C, et al. What's love got to do with it? Explaining adherence to oral antiretroviral pre-exposure prophylaxis for HIV-serodiscordant couples. J Acquir Immune Defic Syndr. 2012;59:463-8.
9. Smith DK, Grohskopf LA, Black RJ, Auerbach JD, Veronese F, Struble KA, et al. Antiretroviral postexposure prophylaxis after sexual, injection-drug use, or other nonoccupational exposure to HIV in the United States. MMWR Recomm Rep. 2005;54(RR02):1-20.
10. Cardo DM, Culver DH, Ciesielski CA, Srivastava PU, Marcus R, Abiteboul D, et al. A case-control study of HIV seroconversion in health care workers after percutaneous exposure. N Engl J Med. 1997;337:1485-90. (Pubitemid 27495773)
11. Management of possible sexual, injection-drug use, or other nonoccupational exposure to HIV, including considerations related to antiretroviral therapy public health service statement. MMWR Recomm Rep. 1998;47(RR17):1-14.
12. Lurie P, Miller S, Hecht F, Chesney M, Lo B. Postexposure prophylaxis after nonoccupational HIV exposure. JAMA. 2000;280(20):1769-73.
13. Lacombe K, Daguenel-Nguyen A, Lebeau V, Fonguernie L, Girard PM, Meyohas MC. Determinants of adherence to non-occupational post HIV exposure prophylaxis. AIDS. 2006;20(2):291-4.
14. Bentz L, Enel P, Dunais B, Durant J, Poizot-Martin I, Tourette-Turgis C, et al. Evaluating counseling outcome on adherence to prophylaxis and follow-up after sexual HIV-risk exposure: a randomized controlled trial. AIDS Care. 2010;22(12):1509-16.
15. Mayer KH, Mimiaga MJ, Gelman M, Grasso C. Raltegravir, tenofovir DF, and emtricitabine for postexposure prophylaxis to prevent the sexual transmission of HIV: safety, tolerability, and adherence. J Acquir Immune Defic Syndr. 2012;59(4):354-9.
16. Mayer KH, Mimiaga MJ, Cohen D, Grasso C, Bill R, VanDerwarker R, et al. Tenofovir DF plus lamivudine or emtricitabine for nonoccupational postexposure prophylaxis (NPEP) in a Boston Community Health Center. J Acquir Immune Defic Syndr. 2008;47(4):494-9. (Pubitemid 351366963)
17. Schechter M, do Lago RF, Mendelson AB, Moreira RI, Moulton LH, Harrison LH, et al. Behavioral impact, acceptability, and HIV incidence among homosexual men with access to postexposure chemoprophylaxis for HIV. J Acquir Immune Defic Syndr. 2004;35:519-25. (Pubitemid 38420661)
18. Siika AM, Nyandiko WM, Mwangi A, Waxman M, Sidle JE, Kimaiyo SN, et al. The structure and outcomes of a HIV postexposure prophylaxis program in a high HIV prevalence setup in western Kenya. J Acquir Immune Defic Syndr. 2009;51(1):47-53.
19. Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011;64(4):383-94.
20. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177-88. (Pubitemid 17189972)
21. Izulla P, McKibben PS, Munyao J, Karanja S, Koima W, Parmeres J, et al. HIV post-exposure prophylaxis in an urban population of female sex workers in Nairobi, Kenya. J Acquir Immune Defic Syndr. 2012;62:220-5.
22. Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629-34. (Pubitemid 27387172)
23. Begg CB. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50(4):1088-101.
24. Duval S, Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics. 2000;56(1):455-63. (Pubitemid 30422636)
25. Sonder GJB, Prins JM, Regez RM, Brinkman K, Mulder J-W, Veenstra J, et al. Comparison of two HIV postexposure prophylaxis regimens among men who have sex with men in Amsterdam: adverse effects do not influence compliance. Sex Transm Dis. 2010;37(11):681-6.
26. Sonder GJB, van den Hoek A, Regez RM, Brinkman K, Prins JM, Mulder J-W, et al. Trends in HIV postexposure prophylaxis prescription and compliance after sexual exposure in Amsterdam, 2000-2004. Sex Transm Dis. 2006;34:288-93. (Pubitemid 46707481)
27. Heuker J, Sonder GJB, Stolte I, Geskus R, van den Hoek A. High HIV incidence among MSM prescribed postexposure prophylaxis, 2000-2009. AIDS. 2012;26(4):505-12.
28. Zheng W, Smith D, Kippax S. Epidemiologically targeted non-occupational post exposure prophylaxis (NPEP) in Australia, 1998-2002. 14th Annual Conference of the Australasian Society for HIV Medicine.
29. Tissot F, Erard V, Dang T, Cavassini M. Nonoccupational HIV post-exposure prophylaxis: a 10-year retrospective analysis. HIV Med. 2010;11(9):584-92.
30. Rey D, Bendiane MK, Bouhnik A-D, Almeda J, Moatti JP, Carrieri MP. Physicians' and patients' adherence to antiretroviral prophylaxis after sexual exposure to HIV: results from South-Eastern France. AIDS Care. 2008;20(5):537-41.
31. Chacko L, Ford N, Sbaiti M, Siddiqui R. Adherence to HIV post-exposure prophylaxis in victims of sexual assault: a systematic review and meta-analysis. Sex Transm Infect. 2012;88(5):335-41.
32. Abrahams N, Jewkes R. Barriers to post exposure prophylaxis (PEP) completion after rape: a South African qualitative study. Cult Health Sex. 2010;12(5):471-84.
33. Roland ME, Neilands TB, Krone MR, Coates TJ, Franses K, Chesney MA, et al. A randomized noninferiority trial of standard versus enhanced risk reduction and adherence counseling for individuals receiving post-exposure prophylaxis following sexual exposures to HIV. Clin Infect Dis. 2011;53(1):76-83.
34. Diaz Brito V, León A, Knobel H, Peraire J, Domingo P, Clotet B, et al. Post-exposure prophylaxis for HIV infection: a clinical trial comparing lopinavir/ritonavir versus atazanavir each with zidovudine/lamivudine. Antivir Ther. 2011;17(2):337-46.
35. Luque A, Hulse S, Wang D, Shahzad U, Tanzman E, Antenozzi S, et al. Assessment of adverse events associated with antiretroviral regimens for postexposure prophylaxis for occupational and nonoccupational exposures to prevent transmission of human immunodeficiency virus. Infect Control Hosp Epidemiol. 2007;28(6):695-701. (Pubitemid 46954756)
36. Aghaizu A, Mercey D, Copas A, Johnson AM, Hart G, Nardone A. Who would use PrEP? Factors associated with intention to use among MSM in London: a community survey. Sex Transm Infect. 2012;89:207-11.
37. Mimiaga MJ, Case P, Johnson CV, Safren SA, Mayer KH. Preexposure antiretroviral prophylaxis attitudes in high-risk Boston area men who report having sex with men: limited knowledge and experience but potential for increased utilization after education. J Acquir Immune Defic Syndr. 2009;50(1):77-83.
38. Krakower DS, Mimiaga MJ, Rosenberger JG, Novak DS, Mitty JA, White JM, et al. Limited awareness and low immediate uptake of pre-exposure prophylaxis among men who have sex with men using an internet social networking site. PLoS One. 2012;7(3):e33119.
39. Liu AY, Grant RM, Buchbinder SP. Preexposure prophylaxis for HIV. JAMA. 2006;296(7):863-5. (Pubitemid 44223110)
40. Vives N, Almeda J, Contreras CA, Garcia F, Campins M, Casabona J, et al. Use of non-occupational HIV post-exposure prophylaxis in Spain (2001-2005). Enferm Infecc Microbiol Clin. 2008;26(9):546-51.
41. Wensing AM, Schneider MM, Schurink CA, Geerlings SE, Boucher CA. Post-exposure prophylaxis following exposure to HIV: adaptation to the situation may be indicated. Ned Tijdschr Geneeskd. 2005;149(27):1485-9. (Pubitemid 40956604)
42. Levy I. Post exposure prophylaxis (PEP) to prevent HIV after sexual exposure in Israel. Harefuah. 2005;144(4):252-4. (Pubitemid 41783179)
43. Mills EJ, Nachega JB, Buchan I, Orbinski J, Attaran A, Singh S, et al. Adherence to antiretroviral therapy in sub-Saharan Africa and North America: a meta-analysis. JAMA. 2006;296(6):679-90. (Pubitemid 44200639)
44. Minas B, Laing S, Jordan H, Mak DB. Improved awareness and appropriate use of non-occupational post-exposure prophylaxis (nPEP) for HIV prevention following a multi-modal communication strategy. BMC Public Health. 2012;12:906.
45. McCarty EJ, Quah S, Maw R, Dinsmore WW, Emerson CR. Post-exposure prophylaxis following sexual exposure to HIV: a seven-year retrospective analysis in a regional centre. Int J STD AIDS. 2011;22(7):407-8.
46. Day S, Mears A, Bond K, Kulasegaram R. Post-exposure HIV prophylaxis following sexual exposure: a retrospective audit against recent draft BASHH guidance. Sex Transm Infect. 2006;82(3):236-7. (Pubitemid 43901594)
47. Landovitz RJ, Fletcher JB, Inzhakova G, Lake JE, Shoptaw S, Reback CJ. A novel combination HIV prevention strategy: post-exposure prophylaxis with contingency management for substance abuse treatment among methamphetamine-using men who have sex with men. AIDS Patient Care STDs. 2012;26(6):320-8.
48. Shoptaw S, Rotheram-Fuller E, Landovitz RJ, Wang J, Moe A, Kanouse DE, et al. Non-occupational post exposure prophylaxis as a biobehavioral HIV-prevention intervention. AIDS Care. 2008;20(3):376-81. (Pubitemid 351451243)
49. Kahn JO, Martin JN, Roland ME, Bamberger JD, Chesney MA, Chambers D, et al. Feasibility of postexposure prophylaxis (PEP) against human immunodeficiency virus infection after sexual or injection drug use exposure: the San Francisco PEP Study. J Infect Dis. 2001;183:707-14. (Pubitemid 32171744)